Table 2 Clinical and epidemiological characteristics of 27 male and 29 female individuals stratified by HCV infection status

No

27

16 (59.3%)

11 (40.7%)

29

16 (37.2%)

13 (30.2%)

Age (years)

53 (49–58)

55 (51–59)

51 (48–54)

0.373

52 (46–60)

54 (47–62)

49 (44–59)

0.496

BMI (kg/m²) (n = 16)

26.4 (25.4–30.6)

25.6 (24.2–26.9)

26.4 (25.8–30.8)

0.441

22.9 (21.1–25.7)

23.0 (20.2–27.8)

22.8 (21.3–24.4)

0.999

Smoker (n = 9)

–

–

 Never

–

–

3 (33.3%)

–

–

8 (61.5%)

 Previous (> 6 months)

–

–

5 (55.6%)

–

–

2 (15.4%)

 Current

–

–

1 (11.1%)

–

–

3 (23.1%)

Route of transmission

(n = 3)

–

–

 Intravenous drug user

–

3 (100.0%)

–

–

3 (50.0%)

–

 Medical and Aesthetic procedures

–

0 (0.0%)

–

–

2 (33.3%)

–

 Work accident

–

0 (0.0%)

–

–

1 (16.7%)

–

Time from clearance (years) (n = 14)

–

2.3 (1.3–3.8)

–

–

–

9.0 (4.0–28.0)

–

–

IFN-λ₄ genotype (rs12979860)

0.589

0.363

 CC

17 (63.0%)

11(68.8%)

6 (54.5%)

15 (53.6%)

8 (53.3%)

7 (53.8%)

 CT

7 (25.9%)

4 (25.0%)

3 (27.3%)

11 (39.3%)

5 (33.3%)

6 (46.2%)

 TT

3 (11.1%)

1 (6.2%)

2 (18.2%)

2 (7.1%)

2 (13.3%)

0 (0.0%)

Stage of liver fibrosis

(n = 3)

–

–

 F0

–

1 (33.3%)

–

–

0 (0.0%)

–

 F1

–

2 (66.7%)

–

–

5 (83.3%)

–

 F2

–

0 (0.0%)

–

–

1 (16.7%)

–

 F3

–

0 (0.0%)

–

–

0 (0.0%)

–

 F4

–

0 (0.0%)

–

–

0 (0.0%)

–

Liver markers

 FIB4 (n = 21)

1.2 (1.0–1.4)

1.3 (1.2–2.0)

1.0 (0.9–1.1)

0.006

1.2 (0.9–1.5)

1.5 (1.0–1.6)

1.0 (0.8–1.2)

0.038

 APRI (n = 21)

0.3 (0.2–0.4)

0.4 (0.3–0.5)

0.2 (0.2–0.3)

0.020

0.3 (0.2–0.3)

0.3 (0.2–0.4)

0.2 (0.2–0.3)

0.023

 AST (mg/dL) (n = 25)

24.0 (19.0–33.0)

28.0 (24.0–38.5)

19.0 (15.5–22.3)

0.008

19.0 (16.0–24.0)

21.5 (16.0–27.8)

19.0 (15.0–20.0)

0.187

 ALT (mg/dL) (n = 26)

27.0 (17.3–37.5)

28.5 (22.5–40.8)

19.0 (14.0–25.5)

0.065

17.5 (13.8–25.0)

19.0 (17.0–28.8)

15.0 (11.8–17.5)

0.053

 GGT (mg/dL) (n = 25)

28.0 (22.0–39.0)

30.0 (22.0–56.0)

28.0 (26.0–33.3)

0.803

15.5 (11.0–34.0)

19.5 (13.3–54.8)

13.5 (10.8–17.8)

0.148

Metabolic syndrome markers

 TyG (n = 21)

8.5 (8.2–8.7)

8.5 (8.1–8.6)

8.7 (8.4–8.9)

0.173

8.2 (7.9–8.5)

8.4 (8.3–8.7)

8.1 (7.9–8.2)

0.060

 METS IR (n = 14)

37.1 (33.7–46.0)

33.7 (32.6–39.7)

40.3 (36.8–46.0)

0.454

28.1 (25.9–34.6)

29.2 (24.4–36.1)

28.0 (26.0–30.1)

0.849